TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
November 13 2020 - 3:05PM
Business Wire
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing
of its underwritten public offering of 23,437,500 shares of its
common stock for net proceeds of approximately $27.5 million, after
deducting underwriting discounts and commissions and estimated
offering expenses payable by TherapeuticsMD. All of the shares in
the offering were sold by TherapeuticsMD.
Cantor Fitzgerald & Co. was the sole bookrunning manager for
the offering.
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was previously
filed with the Securities and Exchange Commission (“SEC”) and
declared effective by the Securities and Exchange Commission (the
“SEC”) on May 5, 2020. A final prospectus supplement and
accompanying prospectus related to the offering have been filed
with the SEC and are available on the SEC’s website at www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering may also be obtained by
contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499
Park Avenue, 6th floor, New York, NY 10022; Email:
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the
unique changes and challenges women experience through the various
stages of their lives with a therapeutic focus in family planning,
reproductive health, and menopause management. The company is
committed to advancing the health of women and championing
awareness of their healthcare issues.
Forward Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that TherapeuticsMD intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as “believes,” “hopes,”
“may,” “anticipates,” “should,” “intends,” “plans,” “will,”
“expects,” “estimates,” “projects,” “positioned,” “strategy” and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control,
that may cause actual results to differ materially, including the
risks and uncertainties associated with market conditions, risks
and uncertainties associated with TherapeuticsMD’s business and
finances in general and other risks described in the sections
titled “Risk Factors” in TherapeuticsMD’s filings with the SEC,
including its most recent Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, the preliminary
prospectus supplement with respect to the offering and other
filings with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201113005643/en/
Investor Contact Nichol Ochsner Vice President Investor
Relations 561-961-1900 Ext. 2088 nochsner@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2024 to May 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From May 2023 to May 2024